Target intelligence / Profile preview

Hepatitis B virus RNA encapsidation process

Molecular classification
Other (Viral RNA packaging process), Encapsidation signal (ɛ) – structural RNA element, Polymerase–RNA complex, Viral core (capsid) protein–RNA complex
01

Overview

Hepatitis B virus RNA encapsidation is a critical step in the HBV life cycle where the pregenomic RNA, containing the epsilon (ɛ) encapsidation signal, is recognized and bound by the HBV polymerase and core (capsid) protein, leading to packaging of the RNA within newly formed capsids[1][3]. This event is necessary for reverse transcription and synthesis of the viral DNA genome. Disruption of the encapsidation process—by interference with the ɛ signal, blocking core protein function, or degrading the RNA—effectively halts HBV replication, making this process an important mechanistic target for antiviral drug development[4][7][8]. To summarize, "Hepatitis B virus RNA encapsidation" is a process, not a classic molecule or receptor, targeted indirectly by inhibiting participating molecular components, most notably the core (capsid) protein and the HBV polymerase interaction with the ɛ signal on pgRNA. This answer reflects scientific nomenclature and current understanding from the cited literature.

Other names
HBV pgRNA encapsidationHBV pregenomic RNA packagingHBV RNA packagingHBV epsilon (ɛ) encapsidation signal
02

Mechanism of action

Inhibition of core protein function to prevent pgRNA encapsidation and nucleocapsid assembly; siRNA/ASO-mediated degradation or suppression of HBV RNA, reducing available pgRNA for encapsidation; Inhibition of RNaseH to destabilize viral replication and block DNA synthesis

03

Biological functions

Viral genome replication (reverse transcription)Pregenomic RNA packagingNucleocapsid assembly
04

Disease associations

Infection (chronic hepatitis B)Liver disease, cirrhosis, hepatocellular carcinoma (indirect via HBV replication)
05

Safety considerations

Risk of immune-mediated liver injury with strong suppression of HBV replicationHepatotoxicity due to rapid changes in viral loadOff-target effects for RNA-targeting therapies (siRNA/ASO)Immune reactivation in patients on immunosuppressive therapy
06

Interacting drugs

Core protein allosteric modulators (CAMs) (e.g., AB-423, ABI-H0731)

3 more in the full profile.

07

Biomarkers

Encapsidated HBV RNA (pgRNA) in serum or cellsHBV DNA levelsHBsAg (hepatitis B surface antigen)Capsid-associated RNA quantification

Beyond the preview

Go deeper on Hepatitis B virus RNA encapsidation process.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus RNA encapsidation process.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call